Latest Insider Transactions at Gilead Sciences, Inc. (GILD)
This section provides a real-time view of insider transactions for Gilead Sciences, Inc. (GILD). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of GILEAD SCIENCES, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of GILEAD SCIENCES, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 10
2024
|
Andrew D Dickinson Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,639
+2.56%
|
-
|
|
Jun 10
2024
|
Daniel Patrick O'Day Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,693
-0.95%
|
$305,045
$65.25 P/Share
|
|
Jun 10
2024
|
Daniel Patrick O'Day Chairman & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,295
+2.04%
|
-
|
|
Jun 10
2024
|
Sandra Patterson SVP, Controllership |
SELL
Payment of exercise price or tax liability
|
Direct |
255
-0.76%
|
$16,575
$65.25 P/Share
|
|
Jun 10
2024
|
Sandra Patterson SVP, Controllership |
BUY
Exercise of conversion of derivative security
|
Direct |
901
+2.62%
|
-
|
|
Jun 10
2024
|
Merdad Parsey Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,744
-1.74%
|
$113,360
$65.25 P/Share
|
|
Jun 10
2024
|
Merdad Parsey Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,820
+3.68%
|
-
|
|
Jun 10
2024
|
Johanna Mercier Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,714
-1.4%
|
$111,410
$65.25 P/Share
|
|
Jun 10
2024
|
Johanna Mercier Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,751
+2.98%
|
-
|
|
Jun 10
2024
|
Deborah H Telman EVP, Corporate Affairs & GC |
SELL
Payment of exercise price or tax liability
|
Direct |
204
-1.38%
|
$13,260
$65.25 P/Share
|
|
Jun 10
2024
|
Deborah H Telman EVP, Corporate Affairs & GC |
BUY
Exercise of conversion of derivative security
|
Direct |
638
+4.15%
|
-
|
|
May 08
2024
|
Jacqueline K Barton Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,310
+8.6%
|
-
|
|
May 08
2024
|
Ted W Love Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,310
+45.01%
|
-
|
|
May 08
2024
|
Javier Rodriguez Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,310
+17.75%
|
-
|
|
May 08
2024
|
Anthony Welters Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,310
+18.42%
|
-
|
|
May 08
2024
|
Harish Manwani Director |
SELL
Payment of exercise price or tax liability
|
Direct |
451
-3.38%
|
$28,864
$64.92 P/Share
|
|
May 08
2024
|
Harish Manwani Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,310
+14.78%
|
-
|
|
Apr 25
2024
|
Deborah H Telman EVP, Corporate Affairs & GC |
SELL
Payment of exercise price or tax liability
|
Direct |
158
-1.11%
|
$10,270
$65.27 P/Share
|
|
Apr 25
2024
|
Deborah H Telman EVP, Corporate Affairs & GC |
BUY
Exercise of conversion of derivative security
|
Direct |
515
+3.48%
|
-
|
|
Apr 01
2024
|
Merdad Parsey Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,000
-2.03%
|
$144,000
$72.96 P/Share
|
|
Mar 10
2024
|
Deborah H Telman EVP, Corporate Affairs & GC |
SELL
Payment of exercise price or tax liability
|
Direct |
846
-5.79%
|
$63,450
$75.12 P/Share
|
|
Mar 10
2024
|
Deborah H Telman EVP, Corporate Affairs & GC |
BUY
Exercise of conversion of derivative security
|
Direct |
2,555
+14.89%
|
-
|
|
Mar 10
2024
|
Sandra Patterson SVP, Controllership |
SELL
Payment of exercise price or tax liability
|
Direct |
790
-2.36%
|
$59,250
$75.12 P/Share
|
|
Mar 10
2024
|
Sandra Patterson SVP, Controllership |
BUY
Exercise of conversion of derivative security
|
Direct |
2,682
+3.9%
|
-
|
|
Mar 10
2024
|
Daniel Patrick O'Day Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
13,782
-2.76%
|
$1,033,650
$75.12 P/Share
|
|
Mar 10
2024
|
Daniel Patrick O'Day Chairman & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
29,940
+2.95%
|
-
|
|
Mar 10
2024
|
Merdad Parsey Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,803
-4.66%
|
$360,225
$75.12 P/Share
|
|
Mar 10
2024
|
Merdad Parsey Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,401
+4.89%
|
-
|
|
Mar 10
2024
|
Andrew D Dickinson Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,505
-3.23%
|
$337,875
$75.12 P/Share
|
|
Mar 10
2024
|
Andrew D Dickinson Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,732
+3.41%
|
-
|
|
Mar 10
2024
|
Johanna Mercier Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,559
-3.71%
|
$341,925
$75.12 P/Share
|
|
Mar 10
2024
|
Johanna Mercier Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,844
+3.9%
|
-
|
|
Feb 29
2024
|
Merdad Parsey Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,230
-8.15%
|
$592,560
$72.74 P/Share
|
|
Feb 28
2024
|
Merdad Parsey Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,000
-1.94%
|
$146,000
$73.18 P/Share
|
|
Feb 02
2024
|
Ted W Love Director |
BUY
Grant, award, or other acquisition
|
Direct |
512
+50.0%
|
-
|
|
Jan 31
2024
|
Merdad Parsey Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
23,709
-18.77%
|
$1,849,302
$78.26 P/Share
|
|
Jan 31
2024
|
Merdad Parsey Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
76,853
+26.72%
|
-
|
|
Jan 31
2024
|
Johanna Mercier Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
22,509
-16.59%
|
$1,755,702
$78.26 P/Share
|
|
Jan 31
2024
|
Johanna Mercier Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
74,055
+24.1%
|
-
|
|
Jan 31
2024
|
Deborah H Telman EVP, Corporate Affairs & GC |
BUY
Grant, award, or other acquisition
|
Direct |
4,646
+28.37%
|
-
|
|
Jan 31
2024
|
Andrew D Dickinson Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
23,410
-15.32%
|
$1,825,980
$78.26 P/Share
|
|
Jan 31
2024
|
Andrew D Dickinson Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
74,961
+21.6%
|
-
|
|
Jan 31
2024
|
Daniel Patrick O'Day Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
79,335
-14.48%
|
$6,188,130
$78.26 P/Share
|
|
Jan 31
2024
|
Daniel Patrick O'Day Chairman & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
230,747
+18.43%
|
-
|
|
Jan 25
2024
|
Deborah H Telman EVP, Corporate Affairs & GC |
SELL
Payment of exercise price or tax liability
|
Direct |
194
-2.67%
|
$15,520
$80.23 P/Share
|
|
Jan 25
2024
|
Deborah H Telman EVP, Corporate Affairs & GC |
BUY
Exercise of conversion of derivative security
|
Direct |
514
+6.6%
|
-
|
|
Jan 16
2024
|
Andrew D Dickinson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-4.69%
|
$425,000
$85.78 P/Share
|
|
Jan 09
2024
|
Johanna Mercier Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
8,242
-9.06%
|
$700,570
$85.23 P/Share
|
|
Dec 13
2023
|
Sandra Patterson SVP, Controllership |
SELL
Payment of exercise price or tax liability
|
Direct |
298
-0.79%
|
$24,734
$83.09 P/Share
|
|
Dec 13
2023
|
Sandra Patterson SVP, Controllership |
BUY
Exercise of conversion of derivative security
|
Direct |
298
+0.4%
|
-
|